NCT02821234

Brief Summary

One-tenth of the population suffers from insomnia, increasing their risk on other health problems such as depression. Self-reported sleep quality only was historically leading for insomnia diagnosis, but more recently a state of 24-hour hyperarousal has been associated with insomnia, either physiological (increased heart rate, higher frequency EEG) or predominant cognitive-emotional hyperarousal (worry, rumination, repetitive thoughts). Strong evidence shows that those suffering from insomnia with physiological hyperarousal are at higher risk of short and long term severe health problems such as inflammation and hypertension than the group without physiological hyperarousal. The neurophysiological basis of these insomnia phenotypes has however barely been investigated, although its results can have major consequences for how this limiting condition will be treated. To support the development of a differential diagnosis of insomnia, structural and functional brain connectivity in insomnia patients with different levels of hyperarousal will be investigated and related to sleep variables. Investigators will compare the insomnia group to a normal sleeping control group. Investigators expect that the emotion processing circuit (amygdala-ventromedial prefrontal cortex) is a) more affected in insomniacs compared to normal sleeping controls and b) the directionality of this effect to depend on the level and type of hyperarousal in insomniacs. Further, investigators expect c) amygdala activity to be positive correlated with physiological hyperarousal level and d) prefrontal activity to be positively correlated with cognitive-emotional hyperarousal level. Investigators expect a higher physiological hyperarousal level to be reflected in affected afferent pathways of the amygdala towards the ventromedial prefrontal cortex and investigators expect higher cognitive-emotional hyperarousal to be related to affected efferent pathways from the ventromedial prefrontal cortex to the amygdala. Investigators expect sleep quality to play a mediating role in both types of hyperarousal and their brain activation patterns in insomnia patients and normal sleeping controls. These data can lead to the definition of new insomnia phenotypes and to new customized and effective insomnia treatment, focused not only on improving sleep but also on changing dysfunctional hyperarousal levels that currently put insomniacs at risk of numerous severe health problems.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2016

Completed
14 days until next milestone

First Posted

Study publicly available on registry

July 1, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 3, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 3, 2017

Completed
Last Updated

August 23, 2017

Status Verified

August 1, 2017

Enrollment Period

7 months

First QC Date

June 17, 2016

Last Update Submit

August 22, 2017

Conditions

Keywords

InsomniaHyperarousal

Outcome Measures

Primary Outcomes (1)

  • Resting state intrinsic connectivity within the emotion processing network by MRI

    During Visit V2 (study termination), up to 3 month after consent signature

Secondary Outcomes (16)

  • Total sleep time obtained by actimetry

    During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)

  • Sleep efficiency obtained by actimetry

    During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)

  • Wake after sleep onset obtained by actimetry

    During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)

  • Sleep latency obtained by actimetry

    During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)

  • Total sleep time obtained by sleep diary

    During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)

  • +11 more secondary outcomes

Study Arms (2)

Insomnia group

EXPERIMENTAL

Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE \<85%) with 10 days actigraphy occurred in the last 2 months

Other: MRI

Control group

EXPERIMENTAL

Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)

Other: MRI

Interventions

MRIOTHER
Control groupInsomnia group

Eligibility Criteria

Age20 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Insomnia group: patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning.
  • control group: no self-reported sleep problems in the last 2 months.
  • years old.
  • Male or female.
  • having given written informed consent to participate in the research project.

You may not qualify if:

  • Night and shift-workers.
  • Psychiatric disorder: clinical mood disorder, anxiety disorder, psychosis, bipolar disorder.
  • For insomnia group: all sleep disorders other than persistent insomnia.
  • For control group: all sleep disorders.
  • Progressive neurological diseases that include restless legs syndrome.
  • Cardiovascular disease other than treated hypertension.
  • Unstable respiratory or endocrinological diseases.
  • Drug addiction, alcohol addiction during the previous 6 months.
  • Having undertaken trans-meridian travel (± 3H) in the previous 1 month.
  • Pregnant or lactating women.
  • Chronic pain.
  • Hypnotic and psychotropic medication taking or stopped less than 5 half-life periods of molecules before screening V0.
  • Patient participating to any other interventional study.
  • For MRI: presence of a ferromagnetic foreign body (in particular certain intracranial clips, certain cardiac valves, intraocular foreign body, or subject having worked with metals), the presence of an implanted pacemaker, subject with cardiac or brain valves of ventricular derivation (risk of maladjustment), claustrophobia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Bordeaux

Bordeaux, 33000, France

Location

Related Publications (1)

  • Sanz-Arigita E, Daviaux Y, Joliot M, Dilharreguy B, Micoulaud-Franchi JA, Bioulac S, Taillard J, Philip P, Altena E. Brain reactivity to humorous films is affected by insomnia. Sleep. 2021 Sep 13;44(9):zsab081. doi: 10.1093/sleep/zsab081.

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2016

First Posted

July 1, 2016

Study Start

September 1, 2016

Primary Completion

April 3, 2017

Study Completion

April 3, 2017

Last Updated

August 23, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share

Locations